These drug developers are all valued at less than four times this year's projected earnings per share.
News & Analysis: Endo International
Investors liked a major credit agency's improved outlook for the drugmaker.
Traders knock down the stock in response to an analyst downgrade.
ENDP earnings call for the period ending March 31, 2019.
ENDP earnings call for the period ending December 31, 2018.
The struggling drug company reported third-quarter 2018 operating results.
ENDP earnings call for the period ending September 30, 2018.
A strong second quarter sends shares higher.
Can these fast-rising biotech stocks keep the momentum going?
Investor optimism pushes shares higher, but there is still a long way to go for a turnaround.